Fig. 3 | Scientific Reports

Fig. 3

From: Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry

Fig. 3

Time to next treatment or death in patients receiving 1 L. (a) Patients who received ASCT in any LoT. (b) Patients who did not receive ASCT in any LoT. 1 L, first line of therapy; ASCT, autologous stem cell transplantation; LoT, line of therapy. Because no patients who received bortezomib + melphalan in 1 L subsequently received ASCT in any LoT, this regimen is not displayed in panel a. Patients with ASCT-only LoTs are excluded from this output. See Supplementary Tables S4.3.2 and S4.3.3 for medians and confidence intervals.

Back to article page